Rigel Pharmaceuticals | RIGL - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Agenus USD -199.08M 22.15M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Celldex Therapeutics USD 714.56M 258.34M 2026-06
Daiichi Sankyo JPY 489.64B 21.08B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Veracyte USD 126.36M 6.37M 2026-06